Related Experiment Video
Updated: Nov 29, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Introduction to "Immunotherapies for Multiple Myeloma"
Massimo Offidani1, Maria Teresa Petrucci2
1Clinica di Ematologia, Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, via Conca, 71, 60126 Ancona, Italy.
Multiple myeloma is a common blood cancer. This study explores its characteristics and impact in hematological oncology.
Area of Science:
- Hematological Oncology
- Cancer Research
Background:
- Multiple myeloma (MM) is the second most prevalent hematological malignancy.
- MM accounts for approximately 10% of all diagnosed blood cancers.
More Related Videos
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...